Officials with Baxter International Inc. have announced the launch of a ready-to-use vancomycin injection in 0.9% sodium chloride in 500 mg, 750 mg and 1 gram presentations.
The launch is an extension of Baxter’s existing vancomycin injection in 5% dextrose in 500 mg, 750 mg and 1 gram presentations and provides an alternative to certain patients who may need to avoid receiving additional dextrose. By providing vancomycin in both saline and dextrose presentations, officials with Baxter explained that they are adding an antibiotic that has appeared on and off of the FDA Drug Shortage list.
Vancomycin saline injection is the second of nine molecules coming out of a collaborative partnership with Celerity Pharmaceuticals, LLC, a company of Water Street Healthcare Partners, to develop new products that use Baxter’s proprietary container technology, enhanced packaging platform, and aseptic filling manufacturing process.
Vancomycin in a premixed presentation, which uses the company’s proprietary frozen Galaxy container technology. It is indicated or the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci.